Retatrutide Triple Agonist
Retatrutide (LY3437943) is a next-generation triple hormone receptor agonist developed by Eli Lilly. It simultaneously activates GLP-1, GIP, and glucagon receptors, making it one of the most powerful metabolic research compounds studied to date. Available in three concentrations for extended research protocols.
Research Highlights
Weight Management Research
Retatrutide has shown some of the most significant weight reduction results in clinical research of any peptide studied to date. Its triple-agonist mechanism targets multiple hormonal pathways simultaneously for superior metabolic effects.
Triple Receptor Agonism
Unlike GLP-1 only or dual GLP-1/GIP agonists, Retatrutide activates three receptors: GLP-1, GIP, and glucagon. This triple action creates a synergistic effect on appetite suppression, insulin secretion, and energy expenditure.
Glucose Metabolism
By activating both GLP-1 and GIP receptors, Retatrutide enhances glucose-dependent insulin secretion and reduces glucagon release. Research explores its potential in metabolic syndrome and insulin resistance models.
Cardiovascular Research
Glucagon receptor activation increases energy expenditure and may have cardioprotective effects. Research is exploring Retatrutide's potential impact on lipid profiles, liver fat, and cardiovascular risk markers.
Mechanism of Action
Retatrutide's power comes from its ability to activate three distinct hormone receptors at once. GLP-1 receptor activation slows gastric emptying, reduces appetite, and stimulates glucose-dependent insulin secretion. This is the same mechanism behind popular GLP-1 drugs like semaglutide.
GIP receptor activation amplifies the insulin response and may improve the tolerability of GLP-1 effects. Research suggests GIP also plays a role in fat storage regulation and bone metabolism.
Glucagon receptor activation is what sets Retatrutide apart from dual agonists. Glucagon increases energy expenditure, promotes fat breakdown in the liver, and raises metabolic rate — creating an additive effect on top of the GLP-1 and GIP actions. This triple synergy is why research shows Retatrutide producing greater effects than any single or dual agonist studied to date.
Technical Data
Research Use Only
All products are intended for laboratory and research purposes only. Not for human consumption, veterinary use, or clinical application. For use by qualified researchers in controlled settings only. These statements have not been evaluated by the FDA.